Biggest changeAdjusted EBITDA is reconciled as follows: Year Ended December 31, 2024 2023 (dollars in thousands) Net loss $ (128,071) $ (148,173) Less: Net loss attributable to noncontrolling interest 36 156 Adjustments: Interest expense 23,547 21,231 Depreciation and amortization (1) 27,062 21,668 Income tax expense (benefit) 21 (22) Equity-based compensation (2) 71,132 66,835 Acquisition expenses (3) 26 977 Litigation costs (4) 2,069 2,298 (Gain) loss on ROU assets (5) 143 (289) Gain on sale of property and equipment (9) — Restructuring costs (6) 2,363 — Loss on extinguishment of debt 3,020 — Adjusted EBITDA $ 1,339 $ (35,319) (1) Includes $0.6 million in impairment expense related to intangible assets that were written off during the year (2) Represents equity-based compensation related to grants made in the applicable year, as well as equity-based compensation related to the timing of the IPO, which includes previously issued stock appreciation rights ("SARs") liability awards, modifications related to transaction vesting units, and grants made in conjunction with the IPO (3) Represents acquisition-related fees, such as legal and advisory fees, that are non-capitalizable (4) Represents certain litigation costs considered outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy (5) Represents gains or losses related to ROU assets that were terminated or subleased in the respective period (6) Represents severance and related costs incurred as part of a corporate restructuring, that took place during 2024, designed to streamline our organizational structure and drive operational efficiencies Results of Operations We operate and manage our business as a single reporting and operating segment, which is to provide healthcare services to our seniors.
Biggest change(2) Represents equity-based compensation related to grants made in the applicable year (3) Represents acquisition-related fees, such as legal and advisory fees, that are non-capitalizable 55 Table of Contents (4) Represents litigation costs considered outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy (5) Represents gains or losses related to ROU assets that were terminated or subleased in the respective period (6) Represents severance and related costs incurred as part of a corporate restructuring designed to streamline our organizational structure and drive operational efficiencies Results of Operations We operate and manage our business as a single reporting and operating segment, which is to provide healthcare services to our seniors.
Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that we define as net loss before interest expense, income taxes, depreciation and amortization expense, acquisition expenses, certain litigation costs, gains or losses on right of use ("ROU") assets, gains or losses on sale of property and equipment, restructuring costs, equity-based compensation expense and loss on extinguishment of debt.
Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, acquisition expenses, certain litigation costs, gains or losses on right of use ("ROU") assets, gains or losses on sale of property and equipment, restructuring costs, equity-based compensation expense, and loss on extinguishment of debt.
Medical Expenses Payable Medical expenses payable includes estimates of our obligations for medical care services that have been rendered on behalf of our members and the members of third-party payors, but for which claims have either not yet been received or processed, loss adjustment expense reserve for the expected costs of settling these claims, and for liabilities related to physician, hospital and other medical cost disputes. 63 Table of Contents We develop estimates for medical expenses incurred but not yet paid (“IBNP”) which includes an estimate for claims incurred but not reported (“IBNR”) and a payable for adjudicated claims.
Medical Expenses Payable Medical expenses payable includes estimates of our obligations for medical care services that have been rendered on behalf of our members and the members of third-party payors, but for which claims have either not yet been received or processed, loss adjustment expense reserve for the expected costs of settling these claims, and for liabilities related to physician, hospital and other medical cost disputes. 62 Table of Contents We develop estimates for medical expenses incurred but not yet paid (“IBNP”) which includes an estimate for claims incurred but not reported (“IBNR”) and a payable for adjudicated claims.
There are a number of limitations related to the use of adjusted gross profit in lieu of loss from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.
There are a number of limitations related to the use of adjusted gross profit in lieu of income (loss) from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.
As the year progresses, our per-member revenue often declines as new members join us, typically with less complete or accurate documentation (and therefore lower risk-adjustment scores), and senior mortality disproportionately impacts our higher-acuity (and therefore greater revenue) members. Medical costs will vary seasonally depending on a number of factors, but most significantly the weather.
As the year progresses, our per-member revenue often declines as new members join us, typically with less complete or accurate documentation (and therefore lower risk-adjustment scores), and senior mortality disproportionately impacts our higher-acuity (and therefore greater revenue) members. Medical costs will vary seasonally depending on a number of factors, but most significantly the seasons.
We routinely take market share from large established players in highly competitive markets, a key source of our health plan membership growth in excess of the industry average. We believe that there are still significant opportunities for future growth even in our most mature markets where we have a 10-30% market share.
We routinely take market share from large established players in highly competitive markets, a key source of our health plan membership growth in excess of the industry average. We believe that there are still significant opportunities for future growth even in some of our most mature markets where we have approximately 10-30% market share.
We believe our MBR is an indicator of our gross profit for our Medicare Advantage plans and demonstrates the ability of our clinical model to produce superior outcomes by identifying and providing targeted care to our high-risk members resulting in improved member health and reduced total population medical expenses.
We believe our MBR is an indicator of our gross profit for our Medicare Advantage plans and demonstrates the ability of our clinical model to produce differentiated outcomes by identifying and providing targeted care to our high-risk members resulting in improved member health and reduced total population medical expenses.
The Company 61 Table of Contents has used the proceeds from the sale of the Notes to repay in full the $215.0 million aggregate principal amount, accrued interest and fees related to the Oxford term loans, as well as certain fees and expenses incurred in connection with the transaction.
The Company 60 Table of Contents has used the proceeds from the sale of the Notes to repay in full the $215.0 million aggregate principal amount, accrued interest and fees related to the Oxford term loans, as well as certain fees and expenses incurred in connection with the transaction.
Moderately adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of estimate. 64 Table of Contents In many situations, the claims amount ultimately settled will be different than the estimate that satisfies the Actuarial Standards of Practice.
Moderately adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of estimate. 63 Table of Contents In many situations, the claims amount ultimately settled will be different than the estimate that satisfies the Actuarial Standards of Practice.
We combine a proprietary technology platform and a high-touch clinical model that enhances our members’ lifestyles and health outcomes while simultaneously controlling costs, which allows us to reinvest savings back into our platform and products to directly benefit the senior consumer.
We combine a proprietary technology platform and a high-touch clinical model that enhances our members’ lifestyles and health outcomes while simultaneously controlling costs, which allows us to reinvest savings back into our platform and products to directly benefit the senior consumers.
In addition, in order to maintain a differentiated value proposition for our members, we continue to invest in innovative product offerings and supplementary benefits to meet the evolving needs of the senior consumer.
In addition, in order to maintain a differentiated value proposition for our members, we continue to invest in innovative product offerings and supplemental benefits to meet the evolving needs of the senior consumer.
These incentives impact financial performance in the year following the CMS Rating Year (for example, CMS’s announcement of the 2025 Ratings occurred in the second half of 2024 and will impact our financial performance in 2026).
These incentives impact financial performance in the year following the CMS Rating Year (for example, CMS’s announcement of the 2026 Ratings occurred in the second half of 2025 and will impact our financial performance in 2027).
Our actual results could vary because of, and our future capital requirements will depend on, many factors, including our growth rate, the timing and extent of spending to expand our presence in existing markets, expand into new markets, increase our sales and marketing activities and develop our technology.
Our actual results could vary because of, and our future capital requirements will depend 59 Table of Contents on, many factors, including our growth rate, the timing and extent of spending to expand our presence in existing markets, expand into new markets, increase our sales and marketing activities and develop our technology.
To combat the healthcare cost increases that typically result, we proactively look to (i) connect with our population early in their enrollment with Alignment to assess 53 Table of Contents their care needs, (ii) develop care plans and engage those members with more chronic, complex health challenges in our clinical model, and (iii) continue to monitor and evaluate our healthier members in a preventative fashion over time.
To combat the healthcare cost increases that typically result, we proactively look to (i) connect with our population early in their enrollment with Alignment to assess their care needs, (ii) develop care plans and engage those members with more chronic, complex health challenges in our clinical model, and (iii) continue to monitor and evaluate our healthier members in a preventative fashion over time.
"Management's Discussion and Analysis of Financial Condition and Results of Operations" found in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 27, 2024. Overview Alignment is a next generation, consumer-centric platform designed to improve the healthcare experience for seniors.
"Management's Discussion and Analysis of Financial Condition and Results of Operations" found in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 27, 2025. Overview Alignment is a next generation, consumer-centric and clinically focused platform designed to improve the healthcare experience for seniors.
For discussion of 2022 items and year-over-year comparisons between 2023 and 2022 that are not included in this Form 10-K, refer to Item 7.
For discussion of 2023 items and year-over-year comparisons between 2024 and 2023 that are not included in this Form 10-K, refer to Item 7.
Additionally, the California HMO plan has achieved a 4 star or greater rating for seven consecutive years. • Effectively Manage the Quality of Care to Improve Member Outcomes: Our care delivery model is based on a clinical continuum through which we have created a highly personalized experience that is unique to each member depending on their personal health and circumstances.
The California HMO plan has achieved a 4 star or greater rating for nine consecutive years. 52 Table of Contents • Effectively Manage the Quality of Care to Improve Member Outcomes: Our care delivery model is based on a clinical continuum through which we have created a highly personalized experience that is unique to each member depending on their personal health and circumstances.
On June 14, 2024, we borrowed $50,000 in aggregate principal amount of the Delayed Draw Term Loans prior to the expiration date for such amount of the Delayed Draw Term Loans of June 30, 2024.
On June 14, 2024, we borrowed $50.0 million in aggregate principal amount of the Delayed Draw Term Loans prior to the expiration date for such amount of the Delayed Draw Term Loans of June 30, 2024.
The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical expenses payable estimates for the most recent two months as of December 31, 2024: Medical Cost PMPM Quarterly Trend Increase (Decrease) in Medical Expenses Payable Increase (Decrease) in Factors (in thousands) (3)% $ (6,300) (2) (4,200) (1) (2,100) 1 2,100 2 4,200 3 6,300 Each period, we re-examine previously established IBNR estimates based on actual claim submissions and other changes in facts and circumstances.
The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical expenses payable estimates for the most recent two months as of December 31, 2025: Medical Cost PMPM Quarterly Trend Increase (Decrease) in Medical Expenses Payable Increase (Decrease) in Factors (in thousands) (3)% $ (9,000) (2) (6,000) (1) (3,000) 1 3,000 2 6,000 3 9,000 Each period, we re-examine previously established IBNR estimates based on actual claim submissions and other changes in facts and circumstances.
We are ultimately responsible for the entirety of the cost of healthcare services related to our member population, in addition to supplemental benefits that we provide to our seniors. Capitation-related expenses are recorded on an accrual basis during the coverage period. Expenses related to fee-for-service contracts are recorded in the period in which the related services are dispensed.
We are ultimately responsible for the entirety of the cost of healthcare services related to our member population, in addition to supplemental benefits that we provide to our seniors. Capitation-related expenses are recorded on an accrual basis during the coverage period.
The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical expenses payable estimates for those periods as of December 31, 2024: Completion Factors Increase (Decrease) in Medical Expenses Payable Increase (Decrease) in Factors (in thousands) (3)% $ 24,600 (2) 16,400 (1) 8,200 1 (8,200) 2 (16,400) 3 (24,600) Medical Cost Per Member Per Month Trend Factors .
The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical expenses payable estimates for those periods as of December 31, 2025: Completion Factors Increase (Decrease) in Medical Expenses Payable Increase (Decrease) in Factors (in thousands) (3)% $ 33,600 (2) 22,400 (1) 11,200 1 (11,200) 2 (22,400) 3 (33,600) Medical Cost Per Member Per Month Trend Factors .
We anticipate that, starting in 2025, the benefit redesign under the Inflation Reduction Act will result in much more moderate seasonality than we have experienced in past years. Members will still pass through the benefit phases, but our share of the total liability will be more consistent through each phase than it has been in the past.
Starting in 2025, the benefit redesign under the Inflation Reduction Act resulted in more moderate seasonality than we have experienced in past years. Members still pass through the benefit phases, but our share of the total liability is more consistent through each phase than it has been in the past.
The amounts payable under this provision were immaterial at December 31, 2024 and December 31, 2023. The premiums we receive from CMS for our members are based on the annual bid that we submit to CMS. These payments represent revenues for providing healthcare coverage, including Medicare Part D benefits. Under the Medicare Part D program, members receive standard drug benefits.
The amounts payable under this provision were immaterial at December 31, 2025 and December 31, 2024. The premium and capitation payments we receive monthly from CMS for our members are based on the annual bid that we submit to CMS. These payments represent revenues for providing healthcare coverage, including Medicare Part D benefits.
According to CMS data, our approximately 209,900 Health Plan Members represent only 5% market share of Medicare Advantage enrollees in our markets. • Drive Growth and Consistent Outcomes Through New Market Expansion: As part of our long-term growth strategy, we may enter new markets with the goal of building brand awareness across our key stakeholders to achieve meaningful market share over time.
As of January 1, 2026, we have approximately 275,300 Health Plan Members, which, according to CMS data, represent only 6% market share of Medicare Advantage enrollees in our markets. • Drive Growth and Consistent Outcomes Through New Market Expansion: As part of our long-term growth strategy, we may enter new markets with the goal of building brand awareness across our key stakeholders to achieve meaningful market share over time.
Interest on the Term Loans was a variable rate equal to (i) the secured overnight financing rate administered by the Federal Reserve Bank of New York for a one-month tenor, subject to a floor of 1.00%, plus (ii) an applicable margin of 6.50%. The interest rate applied during the year ended December 31, 2024 ranged from 11.35% to 11.84%.
Interest on the Term Loans was a variable rate equal to (i) the secured overnight financing rate administered by the Federal Reserve Bank of New York for a one-month tenor, subject to a floor of 1.00%, plus (ii) an applicable margin of 6.50%.
The adjustments are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments in each period to the amount of revenue recognized to reflect changes in the estimated ultimate premium.
The adjustments are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments in each period to the amount of revenue recognized to reflect changes in the estimated ultimate premium. Premiums are also recorded net of estimated uncollectible amounts and retroactive membership adjustments.
Depreciation and amortization expense was $26.9 million and $21.4 million for the years ended December 31, 2024 and 2023, respectively, an increase of $5.5 million, or 25.5%. The increase was primarily due to the amount and timing of our capital expenditures and the associated depreciation relative to 2023.
Depreciation and amortization expense was $30.4 million and $26.9 million for the years ended December 31, 2025 and 2024, respectively, an increase of $3.5 million, or 13.1%. The increase was primarily due to the amount and timing of our capital expenditures and the associated depreciation relative to 2024. Other Expenses Interest expense.
In aggregate, more than 98% of our health plan members are enrolled in plans rated 4 stars and above, meaning the vast majority of members consistently receive a high-quality care experience, as defined under CMS star measurement criteria.
One hundred percent of our health plan members are enrolled in plans rated 4 stars and above, meaning our members consistently receive a high-quality care experience, as defined under CMS star measurement criteria.
Selling, general, and administrative expenses grew at a slower rate than revenue for the year ended December 31, 2024 compared to the year ended December 31, 2023 due to economies of scale gained from Alignment's 2024 membership growth. Depreciation and Amortization.
Selling, general, and administrative expenses as a percentage of revenue decreased for the year ended December 31, 2025 compared to the year ended December 31, 2024 due to economies of scale gained from Alignment's membership growth. Depreciation and Amortization.
Pharmacy costs represent payments for members’ prescription drug benefits, net of rebates from drug manufacturers. Receivables for such manufacturer rebates are included in accounts receivable in the consolidated balance sheet. Selling, General and Administrative Expenses.
Expenses related to fee-for-service contracts are recorded in the period in which the related services are dispensed. 56 Table of Contents Pharmacy costs represent payments for members’ prescription drug benefits, net of rebates from drug manufacturers. Receivables for such manufacturer rebates are included in accounts receivable in the consolidated balance sheet. Selling, General and Administrative Expenses.
Depreciation and amortization expenses are primarily attributable to our capital investment and consist of fixed asset depreciation, amortization of intangibles considered to have definite lives and amortization of capitalized internal-use software costs. Other Expense Interest Expense.
Depreciation and amortization expenses are primarily attributable to our capital investment and consist of fixed asset depreciation, amortization of intangibles considered to have definite lives and amortization of capitalized internal-use software costs. Other Expense Interest Expense. Interest expense consists primarily of interest payments related to the convertible notes that were issued in November 2024.
Overall, medical expenses for the year ended December 31, 2024 grew at a slightly higher rate than earned premium revenues compared to the year ended December 31, 2023, primarily due to 2024 having a higher percentage of new members relative to returning members, richer member benefits and increases in unit costs.
Overall, medical expenses for the year ended December 31, 2025 grew at a lower rate than earned premium revenues compared to the year ended December 31, 2024, primarily due to a higher percentage of new members relative to returning members in 2024 compared to 2025. The increase was offset by increases in unit costs. Selling, General and Administrative Expenses.
Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA in lieu of net loss, which is the most directly comparable financial measure calculated in accordance with GAAP.
There are a number of limitations related to the use of Adjusted EBITDA in lieu of net income (loss), which is the most directly comparable financial measure calculated in accordance with GAAP.
Other states in which our health plans or risk bearing entities operate have chosen not to adopt the RBC rules, but instead have designed and implemented their own rules regarding capital adequacy. As of December 31, 2024, our health plans or risk-bearing entities were in compliance with the minimum capital requirements.
Other states in which our health plans or risk bearing entities operate have chosen not to adopt the RBC rules, but instead have designed and implemented their own rules regarding capital adequacy, such as the tangible net equity ("TNE") requirements for our health plans in California.
Year Ended December 31, (dollars in thousands) 2024 2023 Net cash provided by (used in) operating activities $ 34,770 $ (59,187) Net cash provided by (used in) investing activities 39,191 (147,263) Net cash provided by financing activities 156,028 105 Net change in cash 229,989 (206,345) Cash, cash equivalents and restricted cash at beginning of period 204,954 411,299 Cash, cash equivalents and restricted cash at end of period $ 434,943 $ 204,954 Operating Activities For the year ended December 31, 2024, net cash provided by operating activities was $34.8 million, an increase of $94.0 million compared to net cash used in operating activities of $59.2 million for the year ended December 31, 2023.
Year Ended December 31, (dollars in thousands) 2025 2024 Net cash provided by operating activities $ 139,927 $ 34,770 Net cash provided by (used in) investing activities (14,974) 39,191 Net cash provided by financing activities 18,041 156,028 Net change in cash 142,994 229,989 Cash, cash equivalents and restricted cash at beginning of period 434,943 204,954 Cash, cash equivalents and restricted cash at end of period $ 577,937 $ 434,943 Operating Activities For the year ended December 31, 2025, net cash provided by operating activities was $139.9 million, an increase of $105.2 million compared to net cash provided by operating activities of $34.8 million for the year ended December 31, 2024.
It also excludes approximately 8,300 and 7,300 ACO REACH members as of December 31, 2024 and December 31, 2023, respectively. Adjusted Gross Profit and Medical Benefits Ratio Adjusted gross profit is a non-GAAP financial measure that we define as loss from operations before depreciation and amortization, clinical equity-based compensation expense, clinical restructuring costs and selling, general, and administrative expenses.
We discontinued our participation in the ACO REACH model as of December 31, 2025. Adjusted Gross Profit and Medical Benefits Ratio Adjusted gross profit is a non-GAAP financial measure that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, clinical restructuring costs and selling, general, and administrative expenses.
Key Business Metrics In addition to our financial information in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), we review a number of operating and financial metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions.
GAAP”), we review a number of operating and financial metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions.
Earned premium revenues were $2,671.9 million and $1,800.9 million for the years ended December 31, 2024 and 2023, respectively, an increase of $871.0 million or 48.4%. The increase was primarily driven by growth in our Health Plan membership, which increased 58.6% between December 31, 2024 and December 31, 2023.
Earned premium revenues were $3,911.7 million and $2,671.9 million for the years ended December 31, 2025 and 2024, respectively, an increase of $1,239.8 million or 46.4%. The increase was primarily driven by growth in our Health Plan membership, which increased 25.0% between December 31, 2025 and December 31, 2024 and higher revenue per member per month.
Given our intent to continue to invest in our 55 Table of Contents platform and the scalability of our business in the short to medium-term, we believe Adjusted EBITDA over the long term will be an important indicator of value creation.
Given our intent to continue to invest in our platform and the scalability of our business in the short to medium-term, we believe Adjusted EBITDA over the long term will be an important indicator of value creation. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP.
Financing Activities For the year ended December 31, 2024, net cash provided by financing activities was $156.0 million, an increase of $155.9 million compared to net cash provided by financing activities of $0.1 million for the year ended December 31, 2023.
Financing Activities For the year ended December 31, 2025, net cash provided by financing activities was $18.0 million, a decrease of $138.0 million compared to net cash provided by financing activities of $156.0 million for the year ended December 31, 2024.
Investing Activities For the year ended December 31, 2024, net cash provided by investing activities was $39.2 million, an increase of $186.5 million compared to net cash used in investing activities of $147.3 million for the year ended December 31, 2023.
Investing Activities For the year ended December 31, 2025, net cash used in investing activities was $15.0 million, a decrease of $54.2 million compared to net cash provided by investing activities of $39.2 million for the year ended December 31, 2024.
As of December 31, 2024, our operating parent company (an indirect wholly owned subsidiary of our parent company) had $212.3 million in cash, cash equivalents and short-term investments. 60 Table of Contents We may incur operating losses in the future due to the investments we intend to continue to make in expanding our operations and sales and marketing, in further developing our technology and due to the general and administrative costs we expect to incur in connection with continuing to operate as a public company.
We may incur operating losses in the future due to the investments we intend to continue to make in expanding our operations and sales and marketing, in further developing our technology and due to the general and administrative costs we expect to incur in connection with continuing to operate as a public company.
Prior to the repayment of the Oxford term loans, the average interest rate during 2024 was 11.77% compared to an average interest rate of 11.35% during the year ended December 31, 2023. The convertible notes have an interest rate of 4.25%. Other (income) expenses, net .
The convertible notes have an interest rate of 4.25%, compared to our prior term loans which had an average interest rate of 11.77% for the year ended December 31, 2024.
This was offset by the repayment of $215.0 million related to the Oxford term loans, as discussed above. 62 Table of Contents Material cash requirements from known contractual and other obligations Our principal commitments consist of repayments of long-term debt, operating leases and certain purchase obligations.
This decrease was offset by $18.1 million in proceeds from the exercise of stock options. 61 Table of Contents Material cash requirements from known contractual and other obligations Our principal commitments consist of repayments of long-term debt, operating leases and certain purchase obligations.
Premiums are also recorded net of estimated uncollectible amounts and retroactive membership adjustments. 56 Table of Contents Our recognized premium revenue for the Alignment Health Plans is subject to a minimum annual medical loss ratio (“MLR”) of 85%. The MLR represents medical costs as a percentage of premium revenue.
Our recognized premium revenue for the Alignment Health Plan is subject to a minimum annual medical loss ratio (“MLR”) of 85%. The MLR represents medical costs as a percentage of premium revenue.
Other (income) expenses consist primarily of gains or losses on the disposition of assets, as well as gains and losses related to subleased ROU assets. 57 Table of Contents The following table sets forth our consolidated statements of operations data for the periods indicated: Year Ended December 31, 2024 2023 (dollars in thousands) Revenues: Earned premiums $ 2,671,931 $ 1,800,933 Other 31,630 22,697 Total revenues 2,703,561 1,823,630 Expenses: Medical expenses 2,406,870 1,622,600 Selling, general, and administrative expenses 371,374 307,433 Depreciation and amortization 26,872 21,414 Total expenses 2,805,116 1,951,447 Loss from operations (101,555) (127,817) Other expenses: Interest expense 23,547 21,231 Other (income) expenses, net (72) (853) Loss on extinguishment of debt 3,020 — Total other expenses 26,495 20,378 Loss before income taxes (128,050) (148,195) Provision for income tax expense (benefit) 21 (22) Net loss $ (128,071) $ (148,173) Less: Net loss attributable to noncontrolling interest 36 156 Net loss attributable to Alignment Healthcare, Inc. $ (128,035) $ (148,017) 58 Table of Contents The following table sets forth our consolidated statements of operations data expressed as a percentage of total revenues for the periods indicated: Year Ended December 31, 2024 2023 (% of revenue) Revenues: Earned premiums 99 % 99 % Other 1 1 Total revenues 100 100 Expenses: Medical expenses 89 89 Selling, general and administrative expenses 14 17 Depreciation and amortization 1 1 Total expenses 104 107 Loss from operations (4) (7) Other expenses: Interest expense 1 1 Other (income) expenses, net — — Loss on extinguishment of debt — — Total other expenses 1 1 Loss before income taxes (5) (8) Provision for income taxes — — Net loss (5) (8) Less: Net loss attributable to noncontrolling interest — — Net loss attributable to Alignment Healthcare, Inc.
The following table sets forth our consolidated statements of operations data for the periods indicated: Year Ended December 31, 2025 2024 (dollars in thousands) Revenues: Earned premiums $ 3,911,718 $ 2,671,931 Other 37,001 31,630 Total revenues 3,948,719 2,703,561 Expenses: Medical expenses 3,460,156 2,406,870 Selling, general, and administrative expenses 443,407 371,374 Depreciation and amortization 30,404 26,872 Total expenses 3,933,967 2,805,116 Income (loss) from operations 14,752 (101,555) Other expenses: Interest expense 15,799 23,547 Other income, net (89) (72) Loss on extinguishment of debt — 3,020 Total other expenses 15,710 26,495 Loss before income taxes (958) (128,050) Provision for income tax expense 20 21 Net loss $ (978) $ (128,071) Less: Net loss attributable to noncontrolling interest (254) (36) Net loss attributable to Alignment Healthcare, Inc. $ (724) $ (128,035) 57 Table of Contents The following table sets forth our consolidated statements of operations data expressed as a percentage of total revenues for the periods indicated: Year Ended December 31, 2025 2024 (% of revenue) Revenues: Earned premiums 99.1 % 98.8 % Other 0.9 1.2 Total revenues 100.0 100.0 Expenses: Medical expenses 87.6 89.0 Selling, general, and administrative expenses 11.2 13.7 Depreciation and amortization 0.8 1.0 Total expenses 99.6 103.7 Income (loss) from operations 0.4 (3.7) Other expenses: Interest expense 0.4 0.9 Other income, net — — Loss on extinguishment of debt — 0.1 Total other expenses 0.4 1.0 Loss before income taxes — (4.7) Provision for income tax expense — — Net loss — (4.7) Less: Net loss attributable to noncontrolling interest — — Net loss attributable to Alignment Healthcare, Inc. — % (4.7) % Revenues Year Ended December 31, Change 2025 2024 $ % (dollars in thousands) Revenues: Earned premiums $ 3,911,718 $ 2,671,931 $ 1,239,787 46.4 % Other 37,001 31,630 5,371 17.0 % Total revenues $ 3,948,719 $ 2,703,561 $ 1,245,158 46.1 % Earned Premiums.
Due to the timing of many of these investments, including our primary sales and marketing season, we typically incur a greater level of investment in the second half of the year relative to the first half of the year.
Due to the timing of many of these investments, including our primary sales and marketing season, we typically incur a greater level of investment in the second half of the year relative to the first half of the year. 53 Table of Contents Key Business Metrics In addition to our financial information in accordance with accounting principles generally accepted in the United States of America (“U.S.
AVA’s unified platform, analytical tools and data across the healthcare ecosystem enable us to produce consistent outcomes, unit economics and support new member growth.
AVA’s data insights, combined with the clinical control of our care model, enable us to personalize and manage our member relationships, care quality, and to coordinate and manage risk with our provider partners. AVA’s unified platform, analytical tools and data across the healthcare ecosystem enable us to produce consistent outcomes, unit economics and support new member growth.
The third-party is responsible for arranging and controlling the health care services provided to the ACO members, and for providing certain management and support services with respect to ACO operations. The third-party also assumes specified upside and downside financial risk relative to the ACO’s performance.
In 2024, we entered into a management services and risk management agreement with a third-party healthcare company. The third-party is responsible for arranging and controlling the health care services provided to the ACO members, and for providing certain management and support services with respect to ACO operations.
Adjusted gross profit is reconciled as follows: Year Ended December 31, 2024 2023 (dollars in thousands) Loss from operations $ (101,555) $ (127,817) Add back: Equity-based compensation (medical expenses) 4,930 7,541 Depreciation (medical expenses) 190 254 Restructuring costs (medical expenses) (1) 796 — Depreciation and amortization (2) 26,872 21,414 Selling, general, and administrative expenses 371,374 307,433 Total add back 404,162 336,642 Adjusted gross profit $ 302,607 $ 208,825 (1) Represents severance and related costs incurred as part of a corporate restructuring, that took place during 2024, designed to streamline our organizational structure and drive operational efficiencies (2) Includes $0.6 million in impairment expense related to intangible assets that were written off during the year We calculate our MBR by dividing total medical expenses, excluding depreciation, equity-based compensation and clinical restructuring costs, by total revenues in a given period.
Adjusted gross profit is reconciled as follows: Year Ended December 31, 2025 2024 (dollars in thousands) Income (loss) from operations $ 14,752 $ (101,555) Add back: Equity-based compensation (medical expenses) 6,134 4,930 Depreciation (medical expenses) 78 190 Restructuring costs (medical expenses) (1) — 796 Depreciation and amortization (2) 30,404 26,872 Selling, general, and administrative expenses 443,407 371,374 Total add back 480,023 404,162 Adjusted gross profit $ 494,775 302,607 (1) Represents severance and related costs incurred as part of a corporate restructuring designed to streamline our organizational structure and drive operational efficiencies 54 Table of Contents (2) Amortization expense for the year ended December 31, 2025 includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries.
We may also provide enhanced benefits at our own expense. We recognize revenue for providing this insurance coverage in the month that members are entitled to receive healthcare services. Our CMS payment related to Medicare Part D is subject to risk sharing through the Medicare Part D risk corridor provisions. See “— Critical Accounting Estimates — Revenue” below .
We recognize premium or capitation revenue for providing this insurance coverage in the month that members are entitled to receive health care services and any premium or capitation collected in advance is deferred. Our CMS payment related to Medicare Part D is subject to risk sharing through the Medicare Part D risk corridor provisions.
Liquidity and Capital Resources General To date, we have financed our operations principally through our IPO, private placements of our equity securities, revenues, certain term loans and convertible notes (described below). As of December 31, 2024, we had $470.7 million in cash, cash equivalents and short-term investments. We operate as a holding company in a highly regulated industry.
Other income was $0.1 million and $0.1 million for the years ended December 31, 2025 and 2024. Liquidity and Capital Resources General To date, we have financed our operations principally through our IPO, private placements of our equity securities, revenues, certain term loans and convertible notes (described below).
As a result of this arrangement, revenue is recorded on a net basis within other revenue on the consolidated statement of operations for the year ended December 31, 2024. Expenses Medical Expenses.
The third-party also assumes specified upside and downside financial risks relative to the ACO’s performance. As a result of this arrangement, revenue is recorded on a net basis within other revenue on the consolidated statement of operations for the years ended December 31, 2025 and 2024.
The following table summarizes our contractual and other obligations as of December 31, 2024: Payments due by Period Total Less than 1 year 1-3 year 3-5 years More than 5 years (dollars in thousands) Long term debt obligations (1) $ 330,000 $ — $ — $ 330,000 $ — Operating lease obligations 9,047 1,212 3,525 4,310 — Purchase obligations (2) 50,069 14,695 19,536 13,533 2,305 Other obligations — — — — — Total $ 389,116 $ 15,907 $ 23,061 $ 347,843 $ 2,305 (1) Represents the estimated full cash repayment upon maturity of the Convertible Senior Notes in November 2029.
The following table summarizes our contractual and other obligations as of December 31, 2025: Payments due by Period Total Less than 1 year 1-3 year 3-5 years More than 5 years (dollars in thousands) Long term debt obligations (1) $ 330,000 $ — $ — $ 330,000 $ — Operating lease obligations 8,155 1,873 3,664 2,618 — Purchase obligations (2) 49,354 14,253 26,560 8,541 — Other obligations 270 85 181 4 — Total $ 387,779 $ 16,211 $ 30,405 $ 341,163 $ — (1) Represents the estimated full cash repayment upon maturity of the Convertible Senior Notes in November 2029.
Year Ended December 31, (dollars in '000's, except percentages) 2024 2023 % Change Health plan membership (at period end) 189,100 119,200 58.6 % Medical benefits ratio 88.8 % 88.5 % 0.3 % Revenues $ 2,703,561 $ 1,823,630 48.3 % Loss from Operations $ (101,555) $ (127,817) 20.5 % Net loss $ (128,071) $ (148,173) 13.6 % Adjusted EBITDA (1) $ 1,339 $ (35,319) 103.8 % Adjusted gross profit (1) $ 302,607 $ 208,825 44.9 % (1) See "Adjusted EBITDA" and "Adjusted Gross Profit" below for reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. 54 Table of Contents Health Plan Membership We define Health Plan Membership as the number of members enrolled in our HMO and PPO contracts as of the end of a reporting period.
Year Ended December 31, (dollars in '000's, except percentages) 2025 2024 % Change Health plan membership (at period end) 236,300 189,100 25.0 % Medical benefits ratio 87.5 % 88.8 % (1.3) % Revenues $ 3,948,719 $ 2,703,561 46.1 % Income (loss) from operations $ 14,752 $ (101,555) 114.5 % Net loss $ (978) $ (128,071) 99.2 % Adjusted EBITDA (1) $ 109,944 $ 1,339 8111.1 % Adjusted gross profit (1) $ 494,775 $ 302,607 63.5 % (1) See "Adjusted EBITDA" and "Adjusted Gross Profit" below for reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.
The increase was primarily due to an increase in ongoing investments and expenditures in network development, operations and sales and marketing to drive the growth of Alignment's Health Plan membership.
Selling, general and administrative expenses were $443.4 million and $371.4 million for the years ended December 31, 2025 and 2024, respectively, an increase of $72.0 million, or 19.4%. The increase was primarily due to an increase in ongoing investments and expenditures in operations, network development and sales and marketing to support the growth of Alignment's Health Plan membership.
The following tables provide information about incurred and paid claims development as of December 31, 2024: Cumulative Incurred Claims, net of reinsurance for the Years Ended December 31, 2022 2023 2024 Claims Incurred Year (in thousands) 2022 400,939 385,746 383,865 2023 492,315 484,951 2024 832,819 Total $ 1,701,635 Cumulative Claims paid, net of reinsurance for the Years Ended December 31, Cumulative Number of Paid Claims (1) 2022 2023 2024 Claims Incurred Year (in thousands) 2022 315,187 383,419 382,467 389,689 2023 400,465 481,827 537,129 2024 670,471 909,451 Total $ 1,534,765 (1) Cumulative number of paid claims are presented in whole amounts Substantially all of the claims incurred but not paid balance as of December 31, 2024 relate to the current year.
The following tables provide information about incurred and paid claims development as of December 31, 2025: Cumulative Incurred Claims, net of reinsurance for the Years Ended December 31, 2023 2024 2025 Claims Incurred Year (in thousands) 2022 492,315 482,279 480,412 2023 832,819 809,297 2024 1,136,448 Total $ 2,426,157 Cumulative Claims paid, net of reinsurance for the Years Ended December 31, Cumulative Number of Paid Claims (1) 2023 2024 2025 Claims Incurred Year (in thousands) 2022 400,465 479,148 478,999 540,426 2023 670,471 804,462 1,036,274 2024 848,206 1,268,147 Total $ 2,131,667 (1) Cumulative number of paid claims are presented in whole amounts Substantially all of the claims incurred but not paid balance as of December 31, 2025 relate to the current year.
Alignment Healthcare, Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries.
As of December 31, 2025, we had $604.2 million in cash, cash equivalents and short-term investments. We operate as a holding company in a highly regulated industry. Alignment Healthcare, Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions.
Medical expenses were $2,406.9 million and $1,622.6 million for the years ended December 31, 2024 and 2023, respectively, an increase of $784.3 million, or 48.3%. The increase was driven primarily by the growth in Alignment Health Plan membership, which increased 58.6% between December 31, 2024 and December 31, 2023.
Medical expenses were $3,460.2 million and $2,406.9 million for the years ended December 31, 2025 and 2024, respectively, an increase of $1,053.3 million, or 43.8%.
Additionally, for the year ended December 31, 2024, we recorded amortization expense of $0.6 million related to the impairment of intangible assets associated with an inactive Medicare license that was terminated during the period. Other Expenses Interest expense.
Amortization expense for the year ended December 31, 2024 includes $0.6 million in impairment expense related to intangible assets that were written off during the year.
Factors Affecting Our Performance Our proprietary technology platform, AVA, is a key element of our business with capabilities that we expect to impact our future performance. AVA enables us to personalize and manage our member relationships, care quality and experience, and to coordinate and manage risk with our provider partners.
Factors Affecting Our Performance Our unique clinical model, led by employed clinical teams known as Care Anywhere, acts upon insights derived from our proprietary technology platform, AVA. This integration between our technology and employed care model is a key element of our business with capabilities that we expect to impact our future performance.
We believe this is an important metric to assess growth of our underlying business, which is indicative of our ability to consistently offer a superior value proposition to seniors. This metric excludes third-party payor members with respect to which we are at-risk for managing their healthcare expenditures, which represented 400 members as of December 31, 2024 and December 31, 2023.
Health Plan Membership We define Health Plan Membership as the number of members enrolled in our HMO and PPO contracts as of the end of a reporting period. We believe this is an important metric to assess growth of our underlying business, which is indicative of our ability to consistently offer a superior value proposition to seniors.
The increase primarily relates to purchases of short-term treasury securities which were $379.1 million during the year ended December 31, 2023 compared to $82.2 million during the year ended December 31, 2024, a decrease of 296.9 million. The increase was partially offset by a decrease in maturities of short-term investments.
The increase in cash used primarily relates to reduced investment maturities during the year ended December 31, 2025 compared to the year ended December 31, 2024. The decrease in investment maturities was offset by a decrease in capital expenditures, which decreased $14.6 million for the year ended December 31, 2025 compared to the year ended December 31, 2024 .
Interest expense was $23.5 million and $21.2 million for the years ended December 31, 2024 and 2023, respectively, an increase of $2.3 million or 10.8%. The increase in interest expense was partially due to an increase in the debt balance as a result of the $50.0 million drawdown of the Oxford Delayed Draw term loan in June 2024.
Interest expense was $15.8 million and $23.5 million for the years ended December 31, 2025 and 2024, respectively, a decrease of $7.7 million or 32.8%. The decrease in interest expense was mainly attributable to a decrease in the interest rate on our debt following refinancing in November 2024.
Other revenues increased $8.9 million for the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase is mainly attributable to an increase in the interest rate of our interest earning cash balances.
The decrease in interest rate was offset by an increase in our average long-term debt balance which was $330.0 million for the year ended December 31, 2025 compared to an average balance of $247.5 million for the year ended December 31, 2024. Other income, net .
Additionally, the change from gross to net revenue treatment for ACO REACH increased other revenues by $2.3 million. 59 Table of Contents Expenses Year Ended December 31, Change 2024 2023 $ % (dollars in thousands) Expenses: Medical expenses $ 2,406,870 $ 1,622,600 $ 784,270 48.3 % Selling, general and administrative expenses 371,374 307,433 63,941 20.8 % Depreciation and amortization 26,872 21,414 5,458 25.5 % Total expenses $ 2,805,116 $ 1,951,447 $ 853,669 43.7 % Medical Expenses.
Cash and cash equivalents, and other current investments were $604.2 million as of December 31, 2025 compared to $470.7 million as of December 31, 2024. 58 Table of Contents Expenses Year Ended December 31, Change 2025 2024 $ % (dollars in thousands) Expenses: Medical expenses $ 3,460,156 $ 2,406,870 $ 1,053,286 43.8 % Selling, general and administrative expenses 443,407 371,374 72,033 19.4 % Depreciation and amortization 30,404 26,872 3,532 13.1 % Total expenses $ 3,933,967 $ 2,805,116 $ 1,128,851 40.2 % Medical Expenses.